PharmaShots | Incisive News in 3 Shots

Subscribe Now

Exelixis

Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors

Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors

August 7, 2024

Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors

Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors

February 14, 2023

Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

January 11, 2023

Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

November 4, 2022

Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Cancer

Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Ca...

November 2, 2022

Exelixis Entered into an Exclusive Collaboration Agreement with Cybrexa to Acquire CBX-12 for Solid Tumors

Exelixis Entered into an Exclusive Collaboration Agreement with Cybrexa to Acquire CBX-12 for Solid Tumors

November 2, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us